Marchés
Ultragenyx shares jump 14% after FDA approves first gene therapy
GENGLYCOS granted accelerated approval for glycogen storage disease type Ia, marking Ultragenyx's fifth FDA authorization and first gene therapy. Shares rose 14% in after-hours trading.
Ethan Allen shares rise 4.5% on $3 special dividend declaration
Home furnishings company declares $3 per share special dividend, totaling $76 million, with record date set for September 2026.
Viking Holdings beats Q2 2026 EPS forecast as bookings surge
Cruise operator posts $1.31 adjusted EPS, 37.9% above estimates, as revenue climbs 16.5% and core capacity reaches 96% for 2026. Net income rises 33% year-over-year.
Cambi’s Q2 2026 profit falls as backlog surges to NOK 1.5 bln
Revenue and EBITDA decline amid project completions, while order intake jumps 442% to NOK 554 million. Backlog grows 58% to NOK 1.5 billion, with 46% slated for delivery beyond 2028.
Cogent Communications stock drops 5% after JPMorgan downgrade
JPMorgan cut its rating to Underweight and slashed the price target to $9, citing weaker-than-expected revenue, execution issues in the Waves business and elevated leverage.
German DAX slips 0.07% as tech weakness weighs on gains
The DAX held near flat levels after overnight losses in semiconductor stocks weighed on European equities, while the MDax and Euro Stoxx 50 also slipped modestly. Infineon led declines among DAX tech names.
JPMorgan downgrades Klarna to Neutral, slashes price target to $18
J.P. Morgan cut Klarna’s rating to Neutral from Overweight and reduced its price target to $18, citing weaker-than-expected growth in Europe and a softer outlook for discretionary spending.
Daimler Truck nets €600 million from Archion stake sale
Proceeds from partial Archion divestment fund strategic shift as stake reduced to 25% from over 40% in June. Toyota remains a co-investor in the joint venture.
Les actionnaires de Bleichroeder voteront sur la fusion avec Pasqal la semaine prochaine
La fusion entre Bleichroeder Acquisition Corp. II et la société française spécialisée dans les calculs quantiques Pasqal requiert l’approbation des actionnaires lors d’une réunion prévue le 25 août. La transaction fait suite à l’autorisation de la SEC en août.
Vow ASA swings to Q2 2026 profit as maritime demand strengthens
Norwegian industrial group Vow ASA reported a return to profitability in Q2 2026, driven by maritime segment growth and improved margins, though liquidity pressures persisted amid delayed customer payments.
Les actions de Straumann ont chuté après l'annonce de la démission surprise du PDG
Les actions du fabricant d'implants dentaires chutent de 9,5 % à l'ouverture après la démission inattendue de Guillaume Daniellot, perdant ensuite jusqu'à 6,2 %. Les analystes citent l'incertitude malgré les résultats solides du semestre.
Unitree shares surge over 500% in China debut after IPO
Humanoid robot maker Yushu Technology saw shares jump from 150.8 yuan to peak at 1,100 yuan before paring gains. Demand from retail investors fueled the surge amid broader AI and robotics investment trends.
Geberit shares jump 7.1% on strong first-half sales growth
Swiss plumbing group posts ninth straight quarter of currency-adjusted sales growth, lifts full-year guidance. Shares rise to CHF 564.2.
Ethan Allen shares jump 4.3% on $3 special dividend declaration
Home furnishings retailer Ethan Allen approved a $76 million special payout, the largest in its history, alongside strong fiscal 2026 margins and cash flow. The move follows a governance challenge from a 5% investor.
FTSE 100 edges higher as miners rebound despite UK inflation uptick
UK stocks rise 0.05% as precious-metals miners lead gains, while CPI accelerates to 2.9% in July and energy prices surge 14.7%. Brent crude and WTI slip as gold extends rally.
Elmera Group posts 30% rise in Q2 2026 EBIT as Fortum deal review advances
Norwegian energy group Elmera Group reported a 30.1% increase in adjusted EBIT to NOK 121 million for Q2 2026, while Fortum’s NOK 47 per share cash offer remains under regulatory review.
Swiss SMI edges higher; Geberit surges 8% on strong half-year results
Swiss SMI opens 0.21% higher as Geberit leads gains with an 8% jump following better-than-expected half-year earnings. Implenia, Sensirion and Sunrise also advance, while Straumann, BKW and Emmi decline.
Les actions européennes atteignent des niveaux minimaux en deux semaines ; les rendements des obligations remontent avant les messages de la BCE et de la Fed
L'indice Stoxx Europe 600 chute pour la sixième séance consécutive alors que les rendements atteignent des sommets pluriannuels ; le chef économiste de la BCE met en garde contre les risques persistants d'inflation. Le Trésor américain étend ses programmes d'achat d'obligations.
SQM posts record Q2 2026 profit as lithium rebound boosts revenue to $2.47bn
Net income surged 646% year-over-year to $660 million as lithium prices and volumes soared, while adjusted EBITDA margin reached 53%.
German DAX slips 0.14% as rate jitters persist, chip stocks weigh
The German benchmark index closed modestly lower as rising bond yields and Middle East tensions kept investors cautious. Chip stocks led declines, with Infineon down 4%, while SAP and Merck advanced on positive sector news.
Straumann reports 2.3% revenue growth in H1, CEO Daniellot to step down
Swiss dental implant maker posts 1.38 billion francs in first-half sales, trims full-year outlook amid leadership transition.
Workday forms AI research unit, launches PhD fellowship program
New team will focus on enterprise-grade AI systems while the fellowship provides $50,000 annually to doctoral students in partnership with universities.
Yixin Group posts 31% profit growth in H1 2026 despite share drop
China’s auto financing platform Yixin Group reported a 31% rise in adjusted net profit to RMB 850 million for the first half of 2026, driven by FinTech and SaaS revenue growth. Shares fell 3.8% on the news.
DAX edges higher as tech rebound offsets rate, geopolitical risks
German blue-chip index recovers early losses; chipmakers rebound on deal flow and buybacks. Euro Stoxx 50, MDAX also advance as U.S. futures point higher.
Revelation Biosciences picks Avance Clinical for AKI trial
Contract research organization Avance Clinical will oversee Revelation’s Phase 2/3 TITAN study of its Gemini drug for acute kidney injury, with enrollment expected to begin later in 2026.